Accurate, rapid disease testing
Job no longer available
21-100 employees
Our mission is to leverage science to rapidly detect disease, anytime, anywhere.
Desirable
Oxsed is a social venture founded in April 2020 aiming to minimise the impact of disease on individuals and communities by providing accurate and rapid testing throughout the world. Ultimately creating a world where disease doesn’t disrupt normal life.
The first diagnostic test developed is the Oxsed RaVid Direct - a rapid nucleic acid RT-LAMP test for COVID-19 based on the work of Professors Zhanfeng Cui and Wei Huang, who led a team of 19 researchers from the University of Oxford’s Department of Engineering Science and Oxford Suzhou Centre for Advanced Research (OSCAR). This team won the Royal Academy of Engineering President's Special Awards for Pandemic Service for exceptional engineering achievements in tackling COVID-19 throughout the UK.
In October 2020, the company was acquired by DNAFit Life Sciences, a wholly-owned entity of Hong Kong-based genetics and diagnostic health testing company Prenetics. Prenetics have raised over $70m to invest and grow diagnostics startups. Funds received through the acquisition, and access to Prenetics global network of resources, have enabled Oxsed to rapidly grow in the space of a few months.
Oxsed already has regulatory approval in the UK and EU, and further approvals are in process. Soon Oxsed technology will be helping to tackle disease globally.

Steph
Company Specialist at Welcome to the Jungle
City Centre, Oxford, UK
Wei Huang
(Founder)Associate Professor on Synthetic Biology at University of Oxford. Department of Engineering, University Of Science Oxford and Oxford Suzhou for Advanced Research (OSCAR).
Zhanfeng Cui
(Founder)PhD, DSc, FIChemE, FAIMBE, FREng, Donald Pollock Professor of Chemical Engineering, University of Oxford.
Share this job
